假尿嘧啶核苷作为肾病和肿瘤生物标志物的研究进展

doi:10.3969/j.issn.1673-8640.2019.09.022

摘要/Abstract

摘要：

假尿嘧啶核苷（PU）是尿嘧啶核苷异构体,主要由转运RNA（tRNA）代谢产生,机体不再重新利用,直接从尿液中排出。随着对PU认识的深入,其作为肾病、肿瘤等疾病的生物标志物越来越受到关注。文章对PU的代谢特点、检测方法及其在肾病和肿瘤诊治中的临床价值进行了综述,并展望PU等小分子物质在代谢组学研究方面的意义。

关键词: 假尿嘧啶核苷, 慢性肾脏疾病, 肝癌, 肺癌

Abstract:

Pseudouridine（PU） is the isomeride of uracil nucleoside,which is mainly produced by the metabolism of transfer RNA（tRNA）. PU can not be reused and is eliminated through urine directly. With further study,PU is getting more and more attention as a biomarker. This review describes the metabolic characteristics and determination methods of PU,evaluates the role of PU in the diagnosis and treatment of kidney diseases and cancers,and looks forward to the significance of PU on metabonomics.

Key words: Pseudouridine, Chronic kidney disease, Hepatocellular carcinoma, Lung cancer

中图分类号:

R392.9

陈旭, 冯娟综述, 胡晓波, 王昌富审阅. 假尿嘧啶核苷作为肾病和肿瘤生物标志物的研究进展[J]. 检验医学, 2019, 34(9): 864-867.

CHEN Xu, FENG Juan, HU Xiaobo, WANG Changfu. Research progress of pseudouridine as a biomarker of kidney disease and cancer[J]. Laboratory Medicine, 2019, 34(9): 864-867.

图/表 1

参考文献 33

[1]	DAVIS F F,ALLEN F W.Ribonucleic acids from yeast which contain a fifth nucleotide[J]. J Biol Chem,1957,227(2):907-915.
[2]	LECOINTE F,SIMOS G,SAUER A,et al.Characterization of yeast protein Deg1 as pseudouridine synthase(Pus3) catalyzing the formation of psi 38 and psi 39 in tRNA anticodon loop[J]. J Biol Chem,1998,273(3):1316-1323.
[3]	SAMUELSSON T,OLSSON M.Transfer RNA pseudouridine synthases in Saccharomyces cerevisiae[J]. J Biol Chem,1990,265(15):8782-8787.
[4]	PENZO M,GUERRIERI A N,ZACCHINI F,et al. RNA pseudouridylation in physiology and medicine：for better and for worse[J].Genes（Basel）,2017,8(11):pii:E301.
[5]	ZHAO Y,DUNKER W,YU Y T,et al.The role of noncoding RNA pseudouridylation in nuclear gene expression events[J]. Front Bioeng Biotechnol,2018,6:8.
[6]	XU J,GU A Y,THUMATI N R,et al. Quantification of pseudouridine levels in cellular RNA pools with a modified HPLC-UV assay[J]. Genes(Basel),2017,8(9):pii:E219.
[7]	WAGA S,HANNON G J,BEACH D,et al.The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA[J]. Nature,1994,369(6481):574-578.
[8]	SHIOHARA M,EL-DEIRY W S,WADA M,et al. Absence of WAF1 mutations in a variety of human malignancies[J]. Blood,1994,84(11):3781-3784.
[9]	王昌富,李欣,彭长华,等. 假尿嘧啶核苷测定在肾小球疾病中的临床意义[J].中华肾脏病杂志,1998,14(5):306.
[10]	彭长华,王昌富,李承彬,等. HPLC同时检测血清和尿样中肌酐、假尿苷、尿酸[J]. 色谱,1998,16(2):146-148.
[11]	FACHER E A,BECICH M J,DEKA A,et al.Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene[J]. Cancer,1997,79(12):2424-2429.
[12]	MOUSSES S,OZCELIK H,LEE P D,et al.Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer[J]. Hum Mol Genet,1995,4(6):1089-1092.
[13]	GEHRKE C W,ZUMWALT R W,MCCUNE R A,et al.Quantitative high-performance liquid chromatography analysis of modified nucleosides in physiological fluids,tRNA,and DNA[J]. Recent Results Cancer Res,1983,84:344-359.
[14]	TOMIKAWA C,YOKOGAWA T,KANAI T,et al.N7-methylguanine at position 46(m7G46) in tRNA from thermus thermophilus is required for cell viability at high temperatures through a tRNA modification network[J]. Nucleic Acids Res,2010,38(3):942-957.
[15]	DUDLEY E,BOND L.Mass spectrometry analysis of nucleosides and nucleotides[J]. Mass Spectrom Rev,2014,33(4):302-331.
[16]	CLEMMENSEN O J,KIEFFER M,SJØLIN K E. Pseudouridine excretion in patients with psoriasis[J]. Acta Derm Venereol,1987,67(4):310-314.
[17]	ECKARDT K U,CORESH J,DEVUYST O,et al.Evolving importance of kidney disease:from subspecialty to global health burden[J]. Lancet,2013,382(9887):158-169.
[18]	STEVENS L A,CORESH J,GREENE T,et al.Assessing kidney function-measured and estimated glomerular filtration rate[J]. N Engl J Med,2006,354(23):2473-2483.
[19]	SEKULA P,GOEK O N,QUAYE L,et al.A metabolome-wide association study of kidney function and disease in the general population[J]. J Am Soc Nephrol,2016,27(4):1175-1188.
[20]	NIEWCZAS M A,MATHEW A V,CROALL S,et al.Circulating modified metabolites and a risk of ESRD in patients with type 1 diabetes and chronic kidney disease[J]. Diabetes Care,2017,40(3):383-390.
[21]	HOCHER B,ADAMSKI J.Metabolomics for clinical use and research in chronic kidney disease[J]. Nat Rev Nephrol,2017,13(5):269-284.
[22]	SALVATORE F,RUSSO T,COLONNA A,et al.Pseudouridine determination in blood serum as tumor marker[J]. Cancer Detect Prev,1983,6(6):531-536.
[23]	ITOH K,KONNO T,SASAKI T,et al.Relationship of urinary pseudouridine and 1-methyladenosine to activity of leukemia and lymphoma[J]. Clin Chim Acta,1992,206(3):181-189.
[24]	RASMUSON T,BJÖRK G R,HIETALA S O,et al. Excretion of pseudouridine as an independent prognostic factor in renal cell carcinoma[J]. Acta Oncol,1991,30(1):11-15.
[25]	HELDMAN D A,GREVER M R,SPEICHER C E,et al.Urinary excretion of modified nucleosides in chronic myelogenous leukemia[J]. J Lab Clin Med,1983,101(5):783-792.
[26]	AMURO Y,NAKAOKA H,SHIMOMURA S,et al.Serum pseudouridine as a biochemical marker in patients with hepatocellular carcinoma[J]. Clin Chim Acta,1988,178(2):151-158.
[27]	TAMURA S,AMURO Y,NAKANO T,et al.Urinary excretion of pseudouridine in patients with hepatocellular carcinoma[J]. Cancer,1986,57(8):1571-1575.
[28]	LU J Y,LAI R S,LIANG L L,et al.Evaluation of urinary pseudouridine as a tumor marker in lung cancer[J]. J Formos Med Assoc,1994,93(1):25-29.
[29]	WAALKES T P,ABELOFF M D,WOO K B,et al.Carcinoembryonic antigen for monitoring patients with small cell carcinoma of the lung during treatment[J]. Cancer Res,1980,40(12):4420-4427.
[30]	TAMURA S,FUJIOKA H,NAKANO T,et al.Serum pseudouridine as a biochemical marker in small cell lung cancer[J]. Cancer Res,1987,47(22):6138-6141.
[31]	PÉREZ-RAMBLA C,PUCHADES-CARRASCO L,GARCÍA-FLORES M,et al. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia[J]. Metabolomics,2017,13(5):52.
[32]	JIANG T,LIN Y,YIN H,et al.Correlation analysis of urine metabolites and clinical staging in patients with ovarian cancer[J]. Int J Clin Exp Med,2015,8(10):18165-18171.
[33]	ZHANG T,WU X,KE C,et al.Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling[J]. J Proteome Res,2013,12(1):505-512.